Amgen recently unveiled new data from the Kyprolis and Xgeva clinical development programs at the 16th International Myeloma Workshop in New Delhi.
The company delivered a presentation that detailed the planned overall survival interim analysis of the Phase 3 head-to-head Endeavor trial. According to the results, patients treated with Kyprolis and dexamethasone lived longer than those treated with Velcade and dexamethasone.
Amgen also delivered a presentation showing that Xgeva, in patients with multiple myeloma, was non-inferior to zoledronic acid in delaying bone complications.
"Amgen is committed to advancing innovative treatments for patients with multiple myeloma across the disease continuum, including treatments to help patients live longer and supportive therapies that may help to address its impact," Dr. Sean Harper, executive vice president of Research and Development at Amgen, said. "We look forward to sharing new data on KYPROLIS, demonstrating for the first time an overall survival benefit in relapsed or refractory multiple myeloma over a current standard of care regimen, along with XGEVA data, showing its potential as a novel agent in preventing bone complications in multiple myeloma patients."